Santen Pharmaceutical Co., Ltd.
SNPHFOTCHealthcare● Active
$10.99
+$0.00(+0.00%)
Market Cap$3.5B
P/E Ratio—
52W High$11.45
52W Low$8.88
Santen Pharmaceutical Co., Ltd. (SNPHF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SNPHF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
$0.30
Est. $0.19 · +55.5%
Revenue
$0.51B
Est. $0.48B · +5.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
SNPHF reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $0.13 | — | — | — | $0.44B | — |
| ▲ Q2 FY2026 | May 12, 2026 | $0.19 | $0.30 | +55.5% | $0.51B | $0.48B | +5.0% |
| ▼ Q1 FY2026 | Feb 5, 2026 | $0.19 | $0.16 | -16.7% | $0.47B | $0.48B | -3.7% |
| ▲ Q2 FY2025 | May 13, 2025 | $0.12 | $0.17 | +49.0% | $0.51B | $0.52B | -1.9% |
| ▲ Q1 FY2025 | Feb 6, 2025 | $0.00 | $0.16 | +13437.8% | $0.49B | $0.49B | -0.2% |
| ▼ Q4 FY2024 | Nov 7, 2024 | $0.18 | $0.15 | -17.3% | $0.48B | $0.52B | -7.2% |
| ▲ Q3 FY2024 | Aug 6, 2024 | $0.16 | $0.20 | +23.3% | $0.47B | $0.47B | -0.4% |
| ▼ Q2 FY2024 | May 9, 2024 | $0.10 | $0.00 | -97.9% | $0.52B | $0.52B | -0.2% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$0.13
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
$0.30
EPS Est.
$0.19
EPS Surpr.
+55.5%
Revenue
$0.51B
Q1 FY2026
Feb 5, 2026Miss
EPS Actual
$0.16
EPS Est.
$0.19
EPS Surpr.
-16.7%
Revenue
$0.47B
Q2 FY2025
May 13, 2025Beat
EPS Actual
$0.17
EPS Est.
$0.12
EPS Surpr.
+49.0%
Revenue
$0.51B
Q1 FY2025
Feb 6, 2025Beat
EPS Actual
$0.16
EPS Est.
$0.00
EPS Surpr.
+13437.8%
Revenue
$0.49B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
$0.15
EPS Est.
$0.18
EPS Surpr.
-17.3%
Revenue
$0.48B
Q3 FY2024
Aug 6, 2024Beat
EPS Actual
$0.20
EPS Est.
$0.16
EPS Surpr.
+23.3%
Revenue
$0.47B
Q2 FY2024
May 9, 2024Miss
EPS Actual
$0.00
EPS Est.
$0.10
EPS Surpr.
-97.9%
Revenue
$0.52B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $25.50 | $26.36 | $27.20 | 1 |
| Q1 FY2027 | $36.30 | $37.52 | $38.71 | 1 |
| Q4 FY2026 | $33.42 | $34.55 | $35.64 | 1 |
| Q3 FY2026 | $29.05 | $30.02 | $30.98 | 1 |
| Q2 FY2026 | $20.57 | $21.26 | $21.94 | 1 |
| Q1 FY2026 | $29.98 | $30.98 | $31.97 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $75.4B | $77.4B | $79.3B | 2 |
| Q1 FY2027 | $82.9B | $85.0B | $87.1B | 1 |
| Q4 FY2026 | $76.0B | $77.9B | $79.8B | 2 |
| Q3 FY2026 | $72.1B | $73.0B | $73.9B | 3 |
| Q2 FY2026 | $67.7B | $70.4B | $73.0B | 4 |
| Q1 FY2026 | $73.3B | $77.5B | $81.6B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +55.5% | $10.99 | $10.99 | +0.00% |
| ▼ Q1 FY2026 | Feb 5, 2026 | -16.7% | $9.51 | $9.51 | +0.00% |
| ▲ Q2 FY2025 | May 13, 2025 | +49.0% | $10.03 | $10.03 | +0.00% |
| ▲ Q1 FY2025 | Feb 6, 2025 | +13437.8% | $10.53 | $10.53 | +0.00% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -17.3% | $11.89 | $11.89 | +0.00% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +23.3% | $11.07 | $12.46 | +12.56% |
| ▼ Q2 FY2024 | May 9, 2024 | -97.9% | $10.04 | $10.18 | +1.39% |
| ▲ Q1 FY2024 | Feb 8, 2024 | +29.4% | $9.16 | $9.53 | +4.04% |
Q2 FY2026+0.00%
Report Date
May 12, 2026
EPS Beat/Miss
+55.5%
Price Before
$10.99
Price After
$10.99
Q1 FY2026+0.00%
Report Date
Feb 5, 2026
EPS Beat/Miss
-16.7%
Price Before
$9.51
Price After
$9.51
Q2 FY2025+0.00%
Report Date
May 13, 2025
EPS Beat/Miss
+49.0%
Price Before
$10.03
Price After
$10.03
Q1 FY2025+0.00%
Report Date
Feb 6, 2025
EPS Beat/Miss
+13437.8%
Price Before
$10.53
Price After
$10.53
Q4 FY2024+0.00%
Report Date
Nov 7, 2024
EPS Beat/Miss
-17.3%
Price Before
$11.89
Price After
$11.89
Q3 FY2024+12.56%
Report Date
Aug 6, 2024
EPS Beat/Miss
+23.3%
Price Before
$11.07
Price After
$12.46
Q2 FY2024+1.39%
Report Date
May 9, 2024
EPS Beat/Miss
-97.9%
Price Before
$10.04
Price After
$10.18
Q1 FY2024+4.04%
Report Date
Feb 8, 2024
EPS Beat/Miss
+29.4%
Price Before
$9.16
Price After
$9.53
Avg Beat Reaction+3.32%
Avg Miss Reaction+0.46%
Beat Rate5 / 8 quarters
Largest Move+12.56% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SNPHF ends December
Santen Pharmaceutical Co., Ltd. (SNPHF) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $0.30 — beating the analyst consensus of $0.19 by +55.5%. The next SNPHF earnings date is expected around September 1, 2026.
Each quarter, investors track SNPHF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SNPHF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SNPHF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SNPHF earnings · 5 questionsSanten Pharmaceutical Co., Ltd.'s next earnings report is expected around September 1, 2026. SNPHF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SNPHF historically reports after market close (AMC).
SNPHF earnings datewhen is SNPHF earningsSNPHF next earnings datewhen does SNPHF report earningsSNPHF earnings calendar
▸ Source: FMP · Santen Pharmaceutical Co., Ltd. SEC filings · US GAAP · Santen Pharmaceutical Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026